Blood Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Germ Cell Cancer
KIT pathway is constitutively activated in testicular germ cell tumors
December 29th, 2005
The KIT pathway is constitutively activated in testicular germ cell tumors. "We investigated the expression of KIT (product of c-kit oncogene), gain-of-function mutations, and activation of its downstream signal transduction in human testicular cancers. "KIT was expressed in 88% (22/25) of seminomas and in 44.4% (4/9) of nonseminomas compared to adjacent normal testicular tissue," scientists in Japan report. According to Y. Nakai and colleagues at the Osaka University, Graduate School of Medicine, "Nine of the KIT-expressing seminomas had mutations (40.9%; 9/22) in the e-kit gene; two cases in exon 11 and 7 cases in exon...
Source: Blood Weekly (2005-12-29)
|
